<description>&lt;p&gt;&lt;span style= "font-size: 10.0pt; line-height: 115%; font-family: 'Trebuchet MS',sans-serif; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt; In this episode, editor in chief Joseph E. Safdieh, MD, FAAN, highlights articles about how monoclonal antibodies revolutionized neurologic treatment, why pregabalin link to increased heart failure, and a combined therapy that slows progression in primary progressive aphasia.&lt;/span&gt;&lt;/p&gt;</description>

Neurology Today in 5

American Academy of Neurology

50 years of monoclonal antibodies, pregabalin and heart failure, combined therapy for primary progressive aphasia

NOV 6, 20254 MIN
Neurology Today in 5

50 years of monoclonal antibodies, pregabalin and heart failure, combined therapy for primary progressive aphasia

NOV 6, 20254 MIN

Description

In this episode, editor in chief Joseph E. Safdieh, MD, FAAN, highlights articles about how monoclonal antibodies revolutionized neurologic treatment, why pregabalin link to increased heart failure, and a combined therapy that slows progression in primary progressive aphasia.